Document is current
Any future updates will be listed below
-
Authors
Jarisch, Andrea
Rotz, Seth J. https://orcid.org/0000-0003-2896-1113
Cattoni, Alessandro https://orcid.org/0000-0001-6933-6723
Courbiere, Blandine
Lundy, Scott D. https://orcid.org/0000-0002-0127-4295
Orwig, Kyle E.
Poirot, Catherine
Dalle, Jean-Hugues
Phelan, Rachel https://orcid.org/0000-0001-5252-9991
Diesch-Furlanetto, Tamara
-
Funding
Funding for this research was provided by:
The list for CIBMTR is extensive. Please refer to list provided in manuscript under "Funding".
- License Information
-
More Information
Article History
Received: 23 December 2025
Revised: 3 March 2026
Accepted: 26 March 2026
First Online: 12 May 2026
Competing interests
: AJ: Novartis, Medac, Vertex, Chiesi, Merck. SJR: WCG Clinical Services, Syndax, NMDP. JHD: Jazz, Medac, Neovii, Novartis, Orchard, Pfizer, Sanofi, Vertex. TDF: Jazz, Neovii, MSD, Sobi, Novo-nordisk.
